Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022

Rhea-AI Summary

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) is set to host its inaugural R&D Day on September 26, 2022, at the Nasdaq MarketSite in New York City, from 10:00 a.m. to 12:30 p.m. (ET). The event will also be webcast live on the Company’s website. Interested attendees can register via email. Anebulo is focused on developing solutions for acute cannabinoid intoxication and substance abuse disorder, with its lead product candidate, ANEB-001, in Phase 2 trials.

AUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), will host its inaugural R&D Day on Monday, September 26, 2022, in person at the Nasdaq MarketSite in New York City from approximately 10:00 a.m. to 12:30 p.m. (ET).

The Anebulo R&D Day will also be webcast live on the Company's website https://ir.anebulo.com (under "Investors"). A replay of the webcast and related presentation materials will be made available on the Company’s website following the conclusion of the event.

Investors interested in attending the inaugural R&D Day can register via email at AnebuloIR@mww.com. Advance registration is required. For additional information, please contact Samantha Alphonso at salphonso@mww.com or (212) 827-3746.

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder. Its lead product candidate, ANEB-001, is currently in a Phase 2 clinical trial (www.clinicaltrials.gov/ct2/show/NCT05282797) to evaluate its utility in reversing the negative effects of acute cannabinoid intoxication within one hour of administration. This trial is being run in the Netherlands by the Centre for Human Drug Research (CHDR). ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1). For further information about Anebulo, please visit www.anebulo.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, along with terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” and other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of Anebulo and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including risks attendant to developing, testing and commercializing the company’s product candidates, and those described in Anebulo’s most recent annual report on Form 10-K and in other periodic reports filed with the SEC, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, Anebulo undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005329/en/

Anebulo Pharmaceuticals, Inc.

Scott Anderson

Head of Investor Relations and Public Relations

(858) 229-7063

scott@anebulo.com

Rex Merchant

Chief Financial Officer

(512) 598-0931

IR@anebulo.com

Source: Anebulo Pharmaceuticals, Inc.

FAQ

What is the date of Anebulo Pharmaceuticals' R&D Day?

Anebulo Pharmaceuticals' inaugural R&D Day will be held on September 26, 2022.

Where will the Anebulo Pharmaceuticals R&D Day take place?

The R&D Day will take place at the Nasdaq MarketSite in New York City.

How can I attend the Anebulo Pharmaceuticals R&D Day?

Interested individuals can register by emailing AnebuloIR@mww.com.

What is the focus of Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals focuses on developing solutions for acute cannabinoid intoxication and substance abuse disorder.

What is the status of Anebulo's lead product candidate ANEB-001?

ANEB-001 is currently undergoing Phase 2 clinical trials.